Who Paid My Doc
A Randomised, Double-Blind, Parallel Group Phase III Study to Assess T
Research payments
$5,083,579
Through program year 2025, $5,083,579 in research payments was reported against A Randomised, Double-Blind, Parallel Group Phase III Study to Assess T, across 1,637 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $141,888 | 55 |
| 2024 | Research | $1,172,934 | 521 |
| 2023 | Research | $3,221,471 | 825 |
| 2022 | Research | $547,285 | 236 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
7 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Michael Cohen Boston, MA Named on 85 payments
- Jason Raasch Plymouth, MN Named on 85 payments
- Avner Aliphas Boston, MA Named on 84 payments
- Christopher Brook Boston, MA Named on 84 payments
- Michael Platt Boston, MA Named on 84 payments
- Richard Manes Stratford, CT Named on 44 payments
- Cormac Depan Worcester, MA Named on 42 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.